May 23, 2016 — Mitralign Inc. announced it has raised $39.8 million to date in a Series E equity round of financing. With the Series E financing raised, the company plans to continue growing its platform by pursuing U.S. and CE regulatory approval for the commercialization of their Trialign system in parallel with preparations for commercial launch in Europe of their Mitralign Percutaneous Annuloplasty System (MPAS). This includes completion of the SCOUT early feasibility study in the United States and the initiation of the SCOUT II Study to support the CE Mark in Europe.
Both the Trialign and MPAS Systems feature a customizable therapy solution in concert with an extremely small footprint, which leaves all clinical options open for the physician, a key consideration for a front-line intervention. The Trialign System is currently enrolling patients in an early feasibility investigational device exemption (IDE) study in the United States and is not approved for sale or distribution. The MPAS received CE mark approval in February for the treatment of functional mitral regurgitation (FMR).
For more information: www.mitralign.com
November 17, 2025 
